What Is AOD-9604?
AOD-9604 (Advanced Obesity Drug 9604) is classified as a gh fragment peptide. Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
It is extensively evaluated in laboratory and clinical settings for its potential to drive fat loss without gh side effects. Researchers target AOD-9604 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Research-only. Received GRAS status from FDA as food supplement ingredient. Banned by WADA. Phase 3 trial discontinued due to insufficient efficacy.
How Does AOD-9604 Work?
Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
At the molecular level, AOD-9604 operates through pathways characteristic of the GH Fragment class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with fat loss without gh side effects.
Expected Research Timeline
Weeks 2–4
Early lipolysis effects, especially in abdominal area
Months 2–3
Noticeable fat reduction in visceral stores; improved metabolic markers
Long-Term
Sustained fat loss; may preserve muscle mass better than caloric restriction alone
What Does the Research Say?
The following are key findings from peer-reviewed studies on AOD-9604, indexed on PubMed and equivalent databases:
[1]AOD-9604 lipolysis stimulation in preclinical models
Ng et al. demonstrate AOD-9604 stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting IGF-1 or glucose tolerance.
Evidence: preclinical[2]AOD-9604 clinical safety six randomized controlled trials
Heffernan et al.: Pooled analysis of 6 RCTs showing AOD-9604 is well-tolerated with a safety profile similar to placebo despite limited efficacy signals.
Evidence: moderate[3]AOD-9604 Phase IIb trial short-term fat reduction
12-week Phase IIb trial: 1mg/day AOD-9604 produced 2.6 kg weight loss vs 0.8 kg placebo, with reductions in abdominal fat and improved lipid profiles.
Evidence: moderateSafety & Side Effects
Research-only. Received GRAS status from FDA as food supplement ingredient. Banned by WADA. Phase 3 trial discontinued due to insufficient efficacy.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~5% of users | mild |
| Mild nausea | ~3% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
AOD-9604 is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is AOD-9604 Used?
Route
SubQ
Dose Range
300–300 mcg
Frequency
7x/wk
Cycle
12–12 wk
Timing: Morning fasted
Notes: Take on empty stomach. No effect on blood sugar or IGF-1.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
AOD-9604 vs. Related Compounds
| Compound | Primary Use |
|---|---|
| AOD-9604(this page) | Fat loss without GH side effects |
| MOTS-c | Energy, metabolism, fat loss, longevity |
| Semaglutide | Fat loss, appetite control, cardiovascular benefits |
Where to Source AOD-9604 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a gh fragment peptide. Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
What are the primary research benefits of AOD-9604?
Published research identifies primary mechanisms targeting: Fat loss without GH side effects. These findings come from 3+ peer-reviewed studies indexed in our database.
What is the half-life of AOD-9604?
In published pharmacokinetic data, AOD-9604 demonstrates a half-life of approximately 1 hour.
Is AOD-9604 FDA approved?
AOD-9604 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of AOD-9604?
Reported side effects in published literature include Injection site reaction (~5% of users), Mild nausea (~3% of users). Most are classified as mild in severity.
How is AOD-9604 administered?
In research settings, AOD-9604 is typically administered via SubQ. Take on empty stomach. No effect on blood sugar or IGF-1.
Sources
- AOD-9604 lipolysis stimulation in preclinical models. View on PubMed
- AOD-9604 clinical safety six randomized controlled trials. View on PubMed
- AOD-9604 Phase IIb trial short-term fat reduction. View on PubMed